Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior T ...Middle East

TOKYO, PRINCETON, N.J. and CAMBRIDGE, Mass., Jan. 28, 2025 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib (development code: CLN-081/TAS6417)...

Hence then, the article about taiho pharmaceutical taiho oncology and cullinan therapeutics announce primary endpoint met in phase 2b trial of zipalertinib in patients with non small cell lung cancer harboring egfr exon 20 insertion mutations who have received prior t was published today ( Wednesday 29/01/2025 - 03:07 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior T )

Also on site :

• UK to list 65-year-olds as reservists amid Russia threat claims – Telegraph
• Scott Ritter say he was ‘de-banked’
• AI boom fuels fears of an industry bubble (VIDEO)